Search results
Results from the WOW.Com Content Network
The Tyrer-Cuzek Risk Assessment Calculator was released in 2017 by Jack Cuzick, PhD, whose work has been funded by the Breast Cancer Research Foundation since 2011. The online questionnaire ...
Sir Jack Martin Cuzick [2] (born 11 August 1948) is an American-born British academic, director of the Wolfson Institute of Preventive Medicine in London and head of the Centre for Cancer Prevention. He is the John Snow Professor of Epidemiology at the Wolfson Institute, Queen Mary University of London .
Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells. Many targeted therapies are examples of immunotherapy (using immune mechanisms for therapeutic goals) developed by the field of cancer immunology. Thus, as immunomodulators, they are one type of biological response modifiers.
Lower age of first childbirth, compared to the average age of 24, [50] having more children (about 7% lowered risk per child), and breastfeeding (4.3% per breastfeeding year, with an average relative risk around 0.7 [51] [52]) have all been correlated to lowered breast cancer risk in premenopausal women, but not postmenopausal women, in large ...
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis.It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.
In the clinical trial relevant for the drug's approval, ribociclib significantly improved progression-free survival, that is, the time span the cancer did not get worse. For participants receiving placebo plus letrozole, progression-free survival was 16 months on average, while under ribociclib plus letrozole, progression-free survival was 25 ...
Studies have reported elevated risk of breast cancer, nonmelanoma skin cancer, and cancer of the rectum among nurses who are exposed to these drugs. Other investigations revealed that there is a potential genotoxic effect from anti-neoplastic drugs to workers in health care settings.
The estrogen diethylstilbestrol (DES) is occasionally used to treat prostate cancer through suppression of testosterone production. It was previously used in the treatment of breast cancer, but has been replaced by more effective and less toxic agents. Estrace is an estrogen which was also formerly used for antiandrogen therapy of prostate ...